Published in Breast Cancer Res on April 06, 2011
A Phase I Dose-Escalation Study of IMGN388 in Patients With Solid Tumors | NCT00721669
Tumor-induced osteoclast miRNA changes as regulators and biomarkers of osteolytic bone metastasis. Cancer Cell (2013) 1.62
Emerging targeted agents in metastatic breast cancer. Nat Rev Clin Oncol (2013) 1.59
Strong impact of TGF-β1 gene polymorphisms on breast cancer risk in Indian women: a case-control and population-based study. PLoS One (2013) 0.86
CXCL12, CXCR4 and IFNγ genes expression: implications for proinflammatory microenvironment of breast cancer. Clin Exp Med (2012) 0.84
Tumour-derived miRNAs and bone metastasis. Bonekey Rep (2015) 0.83
Radium-223 inhibits osseous prostate cancer growth by dual targeting of cancer cells and bone microenvironment in mouse models. Clin Cancer Res (2017) 0.81
Discovery and computer aided potency optimization of a novel class of small molecule CXCR4 antagonists. PLoS One (2013) 0.81
ROS-Induced CXCR4 Signaling Regulates Mantle Cell Lymphoma (MCL) Cell Survival and Drug Resistance in the Bone Marrow Microenvironment via Autophagy. Clin Cancer Res (2015) 0.81
Dissecting Tumor-Stromal Interactions in Breast Cancer Bone Metastasis. Endocrinol Metab (Seoul) (2016) 0.80
Antitumour activity of the recombination polypeptide GST-NT21MP is mediated by inhibition of CXCR4 pathway in breast cancer. Br J Cancer (2014) 0.80
Effects of Two Common Promoter Polymorphisms of Transforming Growth Factor-β1 on Breast Cancer Risks in Ahvaz, West South of Iran. Iran J Cancer Prev (2016) 0.80
Cathepsin K in the immunohistochemical diagnosis of melanocytic lesions. Int J Clin Exp Pathol (2014) 0.79
Cathepsin L targeting in cancer treatment. Pharmacol Ther (2015) 0.79
Molecular pathogenesis of bone metastases in breast cancer: Proven and emerging therapeutic targets. World J Clin Oncol (2014) 0.79
Cathepsin K induces platelet dysfunction and affects cell signaling in breast cancer - molecularly distinct behavior of cathepsin K in breast cancer. BMC Cancer (2016) 0.78
The role of osteoclasts in breast cancer bone metastasis. J Bone Oncol (2016) 0.78
Targeting bone metastases starting from the preneoplastic niche: home sweet home. Breast Cancer Res (2011) 0.77
Transcriptional regulation of tenascin-W by TGF-beta signaling in the bone metastatic niche of breast cancer cells. Int J Cancer (2015) 0.77
Bone-Targeted Agents for the Management of Breast Cancer Patients with Bone Metastases. J Clin Med (2013) 0.76
Bifunctional fused polypeptide inhibits the growth and metastasis of breast cancer. Drug Des Devel Ther (2015) 0.76
Cilengitide affects tumor compartment, vascularization and microenvironment in experimental bone metastases as shown by longitudinal ¹⁸F-FDG PET and gene expression analysis. J Cancer Res Clin Oncol (2012) 0.76
BIX01294 suppresses osteoclast differentiation on mouse macrophage-like Raw264.7 cells. Bosn J Basic Med Sci (2013) 0.75
Expression profile of cathepsins indicates the potential of cathepsins B and D as prognostic factors in breast cancer patients. Oncol Lett (2015) 0.75
Prevention of Bone Metastases in Breast Cancer Patients. Therapeutic Perspectives. J Clin Med (2014) 0.75
Synthesis and biochemical evaluation of benzoylbenzophenone thiosemicarbazone analogues as potent and selective inhibitors of cathepsin L. Bioorg Med Chem (2015) 0.75
Molecular changes in pre-metastatic lymph nodes of esophageal cancer patients. PLoS One (2014) 0.75
Epithelial-mesenchymal transitions in development and disease. Cell (2009) 39.17
Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer (2002) 12.45
Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer (2010) 11.16
The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med (2003) 10.67
Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol (2010) 9.29
Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study. Lancet Oncol (2010) 6.47
The metastatic niche: adapting the foreign soil. Nat Rev Cancer (2009) 5.28
Latent bone metastasis in breast cancer tied to Src-dependent survival signals. Cancer Cell (2009) 5.24
Src kinases as therapeutic targets for cancer. Nat Rev Clin Oncol (2009) 4.07
RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis. Nature (2010) 3.66
Tumor-derived JAGGED1 promotes osteolytic bone metastasis of breast cancer by engaging notch signaling in bone cells. Cancer Cell (2011) 3.32
Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Blood (2006) 2.91
Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr Rev (2007) 2.82
The endothelin axis: emerging role in cancer. Nat Rev Cancer (2003) 2.81
Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood (2009) 2.61
Syk, c-Src, the alphavbeta3 integrin, and ITAM immunoreceptors, in concert, regulate osteoclastic bone resorption. J Cell Biol (2007) 2.27
A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases. Proc Natl Acad Sci U S A (2003) 2.23
Platelet and osteoclast beta3 integrins are critical for bone metastasis. Proc Natl Acad Sci U S A (2003) 2.21
RANK/RANKL: regulators of immune responses and bone physiology. Ann N Y Acad Sci (2008) 2.10
Effect of L-000845704, an alphaVbeta3 integrin antagonist, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women. J Clin Endocrinol Metab (2005) 1.94
Hypoxia and TGF-beta drive breast cancer bone metastases through parallel signaling pathways in tumor cells and the bone microenvironment. PLoS One (2009) 1.72
Bone morphogenetic protein 7 in the development and treatment of bone metastases from breast cancer. Cancer Res (2007) 1.63
BMP7, a putative regulator of epithelial homeostasis in the human prostate, is a potent inhibitor of prostate cancer bone metastasis in vivo. Am J Pathol (2007) 1.58
Increased Dickkopf-1 expression in breast cancer bone metastases. Br J Cancer (2007) 1.56
Translating an Antagonist of Chemokine Receptor CXCR4: from bench to bedside. Clin Cancer Res (2008) 1.56
C-SRC tyrosine kinase activity is associated with tumor colonization in bone and lung in an animal model of human breast cancer metastasis. Cancer Res (2003) 1.52
Emerging therapeutic opportunities for skeletal restoration. Nat Rev Drug Discov (2011) 1.48
Doxorubicin in combination with a small TGFbeta inhibitor: a potential novel therapy for metastatic breast cancer in mouse models. PLoS One (2010) 1.44
Bisphosphonates' antitumor activity: an unravelled side of a multifaceted drug class. Bone (2010) 1.40
Inhibition of CXCR4 by CTCE-9908 inhibits breast cancer metastasis to lung and bone. Oncol Rep (2009) 1.29
Inhibition of protein kinase c-Src reduces the incidence of breast cancer metastases and increases survival in mice: implications for therapy. J Pharmacol Exp Ther (2006) 1.26
Promising bone-related therapeutic targets for rheumatoid arthritis. Nat Rev Rheumatol (2009) 1.25
Bone metastasis: pathogenesis and therapeutic implications. Clin Exp Metastasis (2007) 1.23
Phase I safety, pharmacokinetics, and inhibition of SRC activity study of saracatinib in patients with solid tumors. Clin Cancer Res (2010) 1.23
Breast cancer-derived Dickkopf1 inhibits osteoblast differentiation and osteoprotegerin expression: implication for breast cancer osteolytic bone metastases. Int J Cancer (2008) 1.19
Inhibiting activin-A signaling stimulates bone formation and prevents cancer-induced bone destruction in vivo. J Bone Miner Res (2010) 1.18
A cathepsin K inhibitor reduces breast cancer induced osteolysis and skeletal tumor burden. Cancer Res (2007) 1.15
A role for endothelin-2 and its receptors in breast tumor cell invasion. Cancer Res (2004) 1.13
Shedding of RANKL by tumor-associated MT1-MMP activates Src-dependent prostate cancer cell migration. Cancer Res (2010) 1.10
Cilengitide inhibits progression of experimental breast cancer bone metastases as imaged noninvasively using VCT, MRI and DCE-MRI in a longitudinal in vivo study. Int J Cancer (2011) 1.07
Cathepsin K inhibitors as treatment of bone metastasis. Curr Opin Support Palliat Care (2008) 1.07
Activin A circulating levels in patients with bone metastasis from breast or prostate cancer. Clin Exp Metastasis (2006) 1.06
Disruption of CXCR4 enhances osteoclastogenesis and tumor growth in bone. Proc Natl Acad Sci U S A (2007) 1.01
SRC inhibitors in metastatic bone disease. Clin Cancer Res (2006) 0.99
The CXCR4/SDF-1 chemokine axis: a potential therapeutic target for bone metastases? Curr Pharm Des (2010) 0.97
Cathepsin K inhibitors prevent matrix-derived growth factor degradation by human osteoclasts. Bone (2007) 0.97
The cathepsin K inhibitor odanacatib suppresses bone resorption in women with breast cancer and established bone metastases: results of a 4-week, double-blind, randomized, controlled trial. Clin Breast Cancer (2010) 0.91
Integrins in bone metastasis formation and potential therapeutic implications. Curr Cancer Drug Targets (2009) 0.90
Novel bone-targeted strategies in oncology. Clin Cancer Res (2010) 0.88
Bosentan inhibits tumor vascularization and bone metastasis in an immunocompetent skin-fold chamber model of breast carcinoma cell metastasis. Clin Exp Metastasis (2006) 0.87
Tgf-Beta pathway as a therapeutic target in bone metastases. Curr Pharm Des (2010) 0.84
Activin A and bone metastasis. J Cell Physiol (2010) 0.82